IMV Inc. to Present at the H.C. Wainwright 20th Annual Global Investment Conference
Aug. 23, 2018
HALIFAX, Nova Scotia, Aug. 23, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that Chief Executive Officer Frederic Ors and Chief Financial Officer Pierre Labbé will present a corporate update at the H.C. Wainwright 20th Annual Global Investment Conference, which takes place September 5 – 6, 2018, in New York, NY.
IMV’s presentation details include:
-- Date: Thursday, September 6, 2018 -- Time: 12:05 – 12:30 p.m. ET -- Location: The Library (Second Floor), The St. Regis Hotel
There will be a live webcast of IMV’s presentation accessible via the following URL: http://wsw.com/webcast/rrshq28/imv/. The webcast will be archived for 90 days following the live presentation. A copy of the presentation will be available on the Events & Presentations page of IMV’s website: www.imv-inc.com.
IMV Inc., formerly Immunovaccine Inc., is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a combination therapy in multiple clinical studies with Incyte and Merck. Connect at www.imv-inc.com.
Contacts for IMV:MEDIA Mike Beyer, Sam Brown Inc.T: (312) 961-2502 E: firstname.lastname@example.org
INVESTOR RELATIONSPierre Labbé, Chief Financial OfficerT: (902) 492-1819 E: email@example.com
Patti Bank, Managing Director, Westwicke PartnersO: (415) 513-1284T: (415) 515-4572 E: firstname.lastname@example.org